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Observational studies suggest improvements with frequent
hemodialysis (HD), but its true efficacy and safety remain
uncertain. The Frequent Hemodialysis Network Trials Group
is conducting two multicenter randomized trials of 250
subjects each, comparing conventional three times weekly
HD with (1) in-center daily HD and (2) home nocturnal HD.
Daily HD will be delivered for 1.5–2.75 h, 6 days/week, with
target eKt/Vn X0.9/session, whereas nocturnal HD will be
delivered for X6 h, 6 nights/week, with target stdKt/V of
X4.0/week. Subjects will be followed for 1 year. The
composite of mortality with the 12-month change in (i) left
ventricular mass index (LVMI) by magnetic resonance
imaging, and (ii) SF-36 RAND Physical Health Composite
(PHC) are specified as co-primary outcomes. The seven main
secondary outcomes are between group comparisons of:
change in LVMI, change in PHC, change in Beck Depression
Inventory score, change in Trail Making Test B score, change
in pre-HD serum albumin, change in pre-HD serum
phosphorus, and rates of non-access hospitalization or death.
Changes in blood pressure and erythropoeisis will also be
assessed. Safety outcomes will focus on vascular access
complications and burden of treatment. Data will be
obtained on the cost of delivering frequent HD compared to
conventional HD. Efforts will be made to reduce bias,
including blinding assessment of subjective outcomes.
Because no large-scale randomized trials of frequent HD have
been previously conducted, the first year has been
designated a Vanguard Phase, during which feasibility of
randomization, ability to deliver the interventions, and
adherence will be evaluated.
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The prevalence of end-stage renal disease is increasing, the
cost of therapy is high, and the disease and treatment are
associated with significant mortality and loss in patient
quality of life.1–4 In-center three times weekly hemodialysis
(HD) remains the major treatment modality, and the 20%
annual mortality rate of HD patients in the US has changed
little over the last decade.5,6 Improvements in HD delivery
are clearly needed.
In an effort to improve outcomes, some centers have
implemented frequent HD regimens in selected patients.
Typically delivered as either short daily (1.5–3 h/session,
6 days/week) or long nocturnal (6–8 h/session, 5–7 nights/week)
treatments, in-center or at home, frequent HD provides
greater weekly solute clearance and improved ultrafiltration
compared with conventional HD (3–4 h/session, 3 days/
week).7,8 Interdialytic increases in urea, other solutes, and
extracellular fluid volume are dissipated more frequently,
potentially resulting in decreased time averaged solute
concentrations and better volume control.7 Two systematic
reviews have summarized the reported effects of frequent
HD on physiological and health-related quality of life
(HRQL) measures.9,10 Findings were variable, and because
most studies were conducted to obtain preliminary experi-
ence with a novel therapy, they suffered from several
methodological limitations, including small sample sizes,
use of non-ideal control groups, and drop-out and selection
biases.9 Finally, the incremental costs of delivering frequent
HD may be substantial.11 Given the potential benefits and
risks of frequent HD, clinical trials are needed to establish the
safety, efficacy, and cost-effectiveness of frequent HD.
Here, we describe the general design and key methodo-
logical issues for the two FHN randomized trials. The Daily
Trial will examine the effects of in-center daily HD compared
with in-center conventional HD on multiple intermediate
outcomes, focusing on changes in left ventricular mass index
http://www.kidney-international.org t e c h n i c a l n o t e s
& 2007 International Society of Nephrology
Received 22 August 2006; revised 10 October 2006; accepted 24
October 2006
Correspondence: RS Suri, Kidney Clinical Research Unit, Room ELL-119,
London Health Sciences Center, 800 Commissioners Road E., London, Ontario
N6A 4G5, Canada E-mail: rita.suri@lhsc.on.ca
Kidney International (2007) 71, 349–359 349
(LVMI) and HRQL. The Nocturnal Trial will compare home
nocturnal HD with conventional HD on the same outcomes
(Figure 1).
TRIAL PROTOCOLS
Objectives
We will assess trial feasibility during the first 12 months of
enrollment (Vanguard phase – see below). The other main
objectives of these trials are to evaluate the safety, efficacy,
and cost-effectiveness of the two frequent HD interventions,
as well as to characterize these complex therapies (Table 1).
Although it might have been ideal to evaluate the effects of
frequent HD on mortality and other ‘hard’ end points, this
would require over 1500 subjects per trial and several years of
accrual and follow-up. Uncertainties about the feasibility of
randomization and scope of such trials led us to abandon this
strategy. We also recognized that no single surrogate outcome
measure would be likely to capture the potential effects of
frequent HD on the multiple aspects of end-stage renal
disease-associated morbidity. Therefore, the efficacy objec-
tives in these trials are based on changes in HRQL, and in
multiple surrogate and physiological end points. Assessment
of safety will focus on vascular access complications and the
burden of therapy.
Study population, baseline evaluation, and randomization
We are recruiting subjects from 19 centers in the United
States and Canada. Incident and prevalent patients requiring
maintenance dialysis are eligible for participation (Table 2).
After providing informed consent, study subjects are
enrolled into a 6–12 week baseline assessment period, during
which eligibility is confirmed and baseline measurements are
collected. Eligible subjects are then randomly assigned 1:1 to
the frequent HD intervention or control arms, by a central,
web-based program. Randomization is stratified by clinical
center and diabetic status, using permuted blocks. We will
follow subjects in the Daily Trial for 12 months. The follow-
up period is 14 months in the Nocturnal Trial to
accommodate the 4–8 week post-randomization training
period for subjects assigned to nocturnal HD.
Treatment interventions
We undertook an extensive review of published and
unpublished data to determine the method by which to
Excluded
patients
6 times per week
Hemodialysis
Daily trial :   
(6 days per week in-center,
target eKt/V = 0.9/session, 
time 1.5 – 2.75 h)
Nocturnal trial : 
(6 nights per week at home,  
target std Kt / V4.0/week, 
time 6 – 8 h)
3 days per week
Hemodialysis
(target eKt/V  > 1.1/session,  
time < 2.75 h) 
Daily Trial: in-center
Nocturnal Trial: initially 
specified as in-center, but 
being changed to home
1
2
3
4
5
2003 – 2005 ………. .Protocol finalization, ethics submission, forms, and database development 
2006  ………. Start of enrolment 
Continued enrolment
2007 .… …….End of Vanguard Phase 
2008 ………...
2008 – 2009 ………. .Follow-up and 1-year closure visits 
2010 ………. .Data analysis and reporting of results
Screening and recruitment 
Educate patients about study, assess eligibility, obtain consent  
Baseline period (4 – 12 weeks)
Confirm eligibility criteria. 
Pseudo  run-in for daily trial patients, home and training assessment for nocturnal trial patients. 
Collect baseline data, perform MRI, and administer baseline questionnaires.  
Randomization visit  
Confirm study eligibility and consent, central web-based randomization to three or six times/week HD.
Training for home hemodialysis – nocturnal trial only (4 – 8 weeks)a
Collect training data. 
Patient follow-up (daily trial: 12 months; nocturnal trial:  14 months)a 
Collect monthly laboratory and blood pressure data and quarterly medication data, administer 4-month questionnaires. 
Collect events data.
Close-out visit 
Collect final follow-up data, perform follow-up MRI and administer follow-up questionnaires.
Randomization (R)
(250 patients per trial)
1 2 3 
Anticipated:
~ 20%  
of patients 
will have competing 
events of death or
transplantation, or will be 
lost to follow-up 
Patients followed for  
12 or 14 months 
Study
close
out visit 
5 
R 
6 
6
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






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Figure 1 | Study timeline and design. aIf nocturnal Trial protocol changes so that contol arm receives conventional HD at home, training will
occur before randomization and follow-up will be 12 months.
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deliver frequent HD. In each trial, in-center three times
weekly HD will serve as the control arm, with patients
remaining on their pre-study HD prescriptions subject to the
National Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative guidelines.12 Daily HD will be delivered 6
days per week in-center, whereas nocturnal HD will be
delivered 6 nights per week at home. The target frequent HD
prescriptions were based on simulated data that predicted
ample separation in total weekly dialysis hours and clearances
of multiple solutes; including urea, phosphate, and beta-2
microglobulin; between the frequent HD and conventional
HD groups (Table 3).
We considered using solely time and frequency to define
the frequent HD dose owing to simplicity, and because the
measurement of weekly solute clearance is controversial.
However, lower limits for parameters based on urea clearance
were stipulated to provide greater standardization, and
simulations indicated this approach would lead to enhanced
dose separation between treatment arms (Table 3). We also
considered other designs, including a 3-arm comparison of
daily, nocturnal, and conventional HD; as well as a multi-arm
trial of 3 vs 4 vs 5 vs 6 sessions per week in order to
determine the optimum balance between efficacy and
treatment burden. However, statistical power and feasibility
considerations precluded implementation of these designs.
For the Nocturnal Trial, we initially specified that the
control group would receive in-center conventional HD.
However, some had suggested the comparison group should
be home conventional HD, allowing disentanglement of the
effects of increased frequency and time from those of
dialyzing at home. For example, dialyzing at home might
affect HRQL as much, or more than increased HD
frequency.13,14 Further, if the control group dialyzed at night
(e.g., 6–8 h, three nights per week), this would remove
confounding of HD session length and time of day from the
frequency comparison.15 Although methodologically appeal-
ing, to train, implement home modifications, and provide
capital costs for all 250 patients in the trial seemed
impractical. Moreover, many investigators felt that the main
goal of the Nocturnal Trial is not to examine the ‘pure’ effect
or mechanism of effect of frequency per se, but to compare
home nocturnal HD with the current standard of care of
in-center conventional HD. It should be noted that, at the
time of writing, owing to low recruitment rates, we are
revisiting this decision and are in the process of modifying
the Nocturnal Trial protocol such that the control arm will
receive three times weekly conventional HD performed
at home.
OUTCOMES
Safety and treatment burden
The safety of frequent HD remains uncertain.9 Frequent HD
poses theoretical risks of increased vascular access complica-
tions owing to more frequent cannulation, but previous
studies have yielded conflicting results.16–19 Frequent HD
may also result in larger weekly blood losses from the HD
circuit;20 water-soluble vitamin deficiencies; and negative
calcium balance.21 We are carefully monitoring subjects for
Table 1 | Objectives
Feasibility
(1) To establish the feasibility of recruiting and retaining patients in two randomized trials of frequent HD. These are: Daily Trial (6 days vs 3 days
weekly in-center HD) and Nocturnal Trial (6 nights weekly home HD vs 3 days weekly in-center HDa)
(2) To ascertain patient adherence to and acceptance of in-center daily HD and home nocturnal HD, and to identify reasons for discontinuation and
non-adherence to these therapies.
Safety
(3) To assess the safety of in-center daily HD and home nocturnal HD, with particular focus on iron losses, vascular access complications, and
treatment burden. Adverse events related to performing the HD procedure at home will also be assessed in the Nocturnal Trial.
Efficacy
(4) To evaluate the efficacy of in-center daily HD and home nocturnal HD on 2 co-primary outcomes: (i) the composite of mortality with the 1 year
change in left ventricular mass index by magnetic resonance imaging, and (ii) the composite of mortality with the 1 year change in the SF-36
RAND PHC score.
(5) To determine the effect of in-center daily HD and home nocturnal HD on nine secondary outcome domains: (i) cardiovascular structure and
function, (ii) HRQL and physical function, (iii) mental health, (iv) cognitive function, (v) nutrition and inflammation, (vi) mineral metabolism, (vii)
anemia, (viii) hypertension, and (ix) clinical events.
Characterization of the interventions
(6) To better understand the complex therapies of in-center daily HD and home nocturnal HD, by evaluating solute clearance, treatment times,
volume removal, and non-dialytic factors such as differences in the frequency of interaction with the health-care team.
Implementation and Cost-Effectiveness
(7) To determine the ability of multiple individual centers to implement in-center daily HD and home nocturnal HD in practice, and identify barriers
to implementation, including incremental costs of delivery, HD unit scheduling and staffing problems, unsuitability of the home envioronment,
inability to train patients, etc.
(8) To estimate the cost-effectiveness of in-center daily HD and home nocturnal HD compared to three times weekly in-center HD from the insurer’s
perspective.
HD, hemodialysis; HRQL, health-related quality of life; PHC, Physical Health Composite.
aInitially the control arm in the Nocturnal Trial was specified as in-center, although we are considering changing the control arm to 3 days weekly home HD.
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these complications, as well as for complications of home HD
(Table 4).
Finally, subjects and their caregivers may ‘burn-out’ from
intensified treatments. Daily HD patients may tire of coming
to the unit twice as often, whereas those on home nocturnal
HD or their caregivers may burn-out from performing the
treatments themselves. We are collecting multiple measures of
burden, including adherence to therapy, time spent on
treatment-related activities, and modality satisfaction (Table 4).
Efficacy
We will quantify the effects of frequent HD on HRQL, and on
multiple surrogate and physiological end points within nine
health domains. Two co-primary outcomes have been
specified, along with seven main secondary outcomes. We
will also consider several additional endpoints within each of
the nine domains (Table 5).
We considered several criteria in choosing primary
outcomes: (1) biological plausibility that the intervention
would influence the measure; (2) clinical importance of the
measure, or its validity as a surrogate (i.e., proven correlation
between change in the outcome and change in mortality
risk); (3) ability of the outcome to be assessed reliably in the
study population; (4) ability to demonstrate a clinically
significant difference within the proposed sample size; and
(5) potential responsiveness of the outcome to frequent HD
based on prior studies.
Table 2 | Eligibility Criteria
Inclusion criteria
Patients with end-stage renal disease requiring chronic renal replacement therapy
AgeX13 years and weightX30 kg (Daily Trial)
AgeX18 years (Nocturnal Trial)
Achieved mean eKt/VX1.1 on at least two consecutive baseline sessions
Exclusion Criteria
Exclusions that preclude randomization:
Unable or unwilling to follow the study protocol for any reason (including mental incompetence)
Unable or unwilling to provide informed consent or sign the Institutional Review Board-approved consent form
Requires HD 43 times per week owing to medical comorbidity. (Ultrafiltration session on a fourth day per week is not an exclusion criterion).
Currently pregnant, or planning to become pregnant within the duration of follow-up.
Currently on home HD (This criteria may be dropped for the Nocturnal Trial)
Exclusions that may interfere with the successful delivery of the interventions:
History of poor adherence to three times weekly HD or peritoneal dialysis.
Daily Trial: Inability or unwillingness to come for in-center HD 6 days per week, including inability to arrange adequate transportation.
Nocturnal Trial: Home environment unsuitable for performing home HD.
Nocturnal Trial: Expected inability to successfully complete the home nocturnal HD training protocol for any reason (e.g., both patient and caregiver
are likely unable to be trained, or patient unable and no suitable caregiver exists).
Geographic unavailability which may preclude receiving frequent HD for a prolonged period, that is:
Daily Trial: Expected geographic unavailability at a participating HD unit for 42 consecutive weeks or 44 weeks total during follow-up.
Nocturnal Trial: Expected geographic unavailability at a participating HD unit for 42 consecutive weeks or 45 weeks total during
follow-up.
Currently in an acute or chronic care hospital.
Contraindication to heparin, including allergy- or heparin-induced thrombocytopenia.
Exclusions that may interfere with the effect of the interventions:
Expectation that native kidneys will recover.
Significant residual renal clearance, that is:
Daily Trial: residual renal clearance 43 ml/min per 35 l urea volume (as determined by urine collection obtained over at least 24 h and urea kinetic
modeling determination of V).
Nocturnal Trial: glomerular filtration rate 410 ml/min per 1.73 m2 (as measured by the average of urea and creatinine clearances from urine
collection obtained over at least 24 h).
Currently on daily or nocturnal HD or less than 3 months as the patient discontinued daily or nocturnal HD.
Less than 3 months as patient returned to HD after kidney transplantation or use of an alternative dialysis modality (such as peritoneal dialysis).
Current use of investigational drugs or participation in another clinical trial
Exclusions that may interfere with complete follow-up or measurement of the primary or safety outcomes:
Scheduled for living donor kidney transplant, change to peritoneal dialysis, or plans to relocate to a non-study center within the follow-up period.
Life expectancy less than 6 months.
Medical history that might limit the patient’s ability to take the trial treatments and complete the full duration of follow-up, including: currently
receiving chemo or radiotherapy for a malignant neoplastic disease other than localized non-melanoma skin cancer, active systemic infection
(including tuberculosis, disseminated fungal infection, active AIDS), and cirrhosis with encephalopathy.
Medical conditions that would prevent the patient from receiving the cardiac MRI procedure (e.g., inability to remain still for the procedure, a
metallic object in the body that is a contraindication to MRI such as cardiac pacemaker, cochlear implant, brain aneurysm clips, mechanical
heart valves, recently placed artificial joints, and older vascular stents).
Inability to communicate verbally in English or Spanish.
Vascular access being used for HD is a non-tunneled catheter.
AIDS, acquired immunodeficiency syndrome; HD, hemodialysis; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging.
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We selected two co-primary outcomes fulfilling these
criteria, and providing complementary information. The SF-
36 RAND Physical Health Composite (PHC) score is a valid
measure of HRQL,22 and lower SF-36 physical function
scores have been linked with higher mortality rates in end-
stage renal disease in multiple studies.23–25 However, despite
its clinical importance, the PHC is a self-reported measure
that may be influenced by subjects’ knowledge of treatment
Table 3 | Frequent HD prescriptions
Parameter
In-center conventional HDa
(Control arm both trials)
In-center daily HD (Daily
Trial)
Home nocturnal HD
(Nocturnal Trial)
Target prescription
Sessions per week 3 days 6 days 6 nights
Target urea clearance eKt/VX1.1 per session eKt/Vn
b=0.90 per session stdKt/VX4.0 per week
Target session time X2.5 h 1.50–2.75 h X6 h
Estimated parameters for study populationc (presented as median, 5th–95th percentile)
Hours per session 3.5 (3.0–0.4.4) 2.4 (1.9–.2.6) 7.0 (6.1–9)
Hours per week 10.5 (9.0–13.1) 14.2 (11.5–16.5) 42.4 (36.6–47.6)
eKt/Vurea per Session 1.39 (1.12–1.75) 0.92 (0.74–1.05) 1.56 (1.0–2.3)
StdKt/Vurea per week 2.5 (2.2–2.8) 3.8 (3.3–4.2) 5.6 (4.3–.6.6)
Weekly standardized phosphate removal
(mg/wk)
299 (254–374) 415 (338–497) 1191d (1028–338)
Equivalent renal clearance of beta-2
microglobulin (ml/min per 35 l urea
volume)
4.8 (3.8–6.2) 5.4 (4.3–6.8) 9.1e (7.1–11.4)
HD, hemodialysis; wk, week.
aWe are in the process of considering modifications to the Nocturnal Trial protocol such that the control arm will receive three times weekly conventional HD performed at
home rather than in-center. However, the prescription parameters will not change.
bNormalized V=Vn=3.271*V
2/3.
cEstimates are based on simulations assuming distributions of patient characteristics and baseline HD prescriptions from a subsample of 100 patients from Renal Research
Institute Database, n=3285, (median V in subsample=34.5 l, 5th–95th percentiles=24.1–46.9 l). The nocturnal HD estimates assume the following: treatment time is distributed
uniformly between 6–8 h, 50% of patients are using single needle HD with dialysis blood flow distributed uniformly from 300 to 500 ml/min, 50% of patients are using
double needle HD with dialysis blood flow distributed uniformly from 200 to 300 ml/min, dialysate flow is distributed uniformly from 200 to 300 ml/min, effective urea KoA is
450 ml/min.
dAssumes pre-dialysis phosphate of 5 mg/dl.
eIncludes extrarenal elimination of beta-2 microglobulin of 3 ml/min.
Table 4 | Safety outcome measures
Category Outcome
Vascular access complications Time to first access intervention
Time to first access failure
Rate of all access interventions
Rate of all access failures
Rate of infection-related access failures
Rate of access hospitalizations.
Iron losses Cumulative intravenous iron requirements over entire follow-up period
Serum ferritin and transferrin saturation.
Metabolic complications Proportion of patients with hypophosphatemia or hyperparathyroidism (Nocturnal Trial)
Vitamin C deficiency (Daily Trial ancillary study).
Catastrophic events related to
home HD (Nocturnal Trial)
Proportion of patients who die during the HD session, or are hospitalized owing to an event occurring during, or
immediately after the HD session
Proportion of patients who die at home
Proportion of HD sessions requiring premature discontinuation for medical or technical reasons (including
bloodline disconnection, and air embolism, etc.).
Patient burn-out and treatment
burden
Caregiver burden as perceived by patients
Proportion of patients requiring dialysis modality change or change in HD frequency
Monthly average number of missed treatments
Weekly average number of shortened treatments
Time spent traveling to and from, and waiting before and after HD treatments (Daily Trial)
Time spent setting up and cleaning up HD machine (Nocturnal Trial)
Time to recovery from the HD session as perceived by patients
Proportion of patients wishing to continue, or switch to, frequent HD at end of follow-up.
HD, hemodialysis.
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assignments in an unblinded trial, rendering it less appealing
as a stand-alone primary outcome. LVMI as measured by
cine-magnetic resonance imaging is an objective measure of
cardiovascular structure and a valid surrogate outcome:
studies have suggested that changes in LVMI are linked with
changes in mortality in HD patients.26–28 Both the SF-3629,30
and LVMI30–33 have been suggested to be responsive to
frequent HD in previous studies. We incorporated mortality
as a component of both primary outcomes, because of its
obvious clinical importance, and its inclusion abrogates
the potential risk of informative censoring in case of
differential mortality rates between the frequent HD and
control groups.
We selected seven main secondary outcomes, based on
clinical importance and validity of the measures, in order to
provide a more comprehensive assessment of the effects of
frequent HD on multiple health domains. Although changes
in blood pressure and erythropoeisis will be assessed, we did
not specify these as main secondary outcomes because their
interpretation is complicated by concurrent medication use
and measurement considerations (Table 5).
Economic evaluation
Each trial will empirically estimate the incremental costs of
providing frequent HD, including direct costs (disposables,
equipment, personnel, training for nocturnal HD, monitor-
ing of nightly HD) and indirect costs (HD unit overhead).
Although the trials are not powered to evaluate a definitive
economic benefit of frequent HD, we are collecting costs
related to hospitalizations, medications covered by Medicare,
and other Medicare-covered services to estimate cost-
effectiveness and cost-utility from the insurer’s perspective.
Some patient direct costs will also be captured, including
medications not covered by Medicare, transportation for
Table 5 | Efficacy outcome measures
Domain Outcome
Co-primary outcomes:
HRQL and physical function Composite of 1-year mortality and change in SF-36 PHC scorea
Cardiovascular structure and
function
Composite of 1-year mortality and change in left-ventricular mass index by cine-MRI
Secondary outcomes:
HRQL and physical function SF-36 RAND PHC scorea
Health-Utilities Index score
Feeling Thermometer score
Medical Outcomes Sleep Scale score
Lower Extremity Performance Battery score (gait time, time to stand, standing balance)
Cardiovascular structure and
function
Left-ventricular mass index by cine-MRIa
End-diastolic, end-systolic, and stroke volumes; ejection fraction; cardiac output
Heart rate variability measures (Daily Trial only)
Rate of intradialytic hypotension episodes
Interdialytic weight gain
Hypertension (No main secondary outcome specified)
Weekly average pre-dialysis systolic blood pressure
Weekly average pre-dialysis pulse pressure
Weekly time averaged home systolic blood pressure (Nocturnal Trial)
Proportion of patients with weekly average pre-dialysis systolic blood pressure o110 mmHg
Number of prescribed antihypertensive agents.
Mental health Beck Depression Inventory scorea
Cognitive function Trail-Making B scorea
Modified Mini-Mental Status score
Nutrition and inflammation Pre-dialysis serum albumina
Normalized protein catabolic rate
Body mass index
Weekly cumulative interdialytic weight gain
Lean body mass by single frequency bioimpedance analysis
Mineral metabolism Pre-dialysis serum phosphatea
Pre-dialysis serum calcium
Pre-dialysis calcium-phosphate product
Pre-dialysis parathyroid hormone
Phosphate binder dose, Vitamin D analog dose
Anemia (No main secondary outcome specified)
Pre-dialysis hemoglobin
Erythropoietin dose normalized for hemoglobin and patient weight
Clinical events Rate of non-access hospitalizations or deatha
Rate of all hospitalizations or death
Rate of cardiovascular hospitalizations or death
Total hospital days per patient-year
HRQL, health-related quality of life; PHC, Physical Health Composite; MRI, magnetic resonance imaging.
aMain secondary outcome measure within the domain.
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daily HD, travel for home HD training, home modifications,
and utilities (water and electricity).
STATISTICAL ANALYSIS
Primary and secondary analyses
We will analyze outcomes for all subjects according to
randomized treatment assignment, irrespective of adherence
to the assigned HD regimen (intention-to-treat analysis).
Except for those who withdraw consent, we will aim to collect
vital status and the primary and main secondary outcomes
for subjects who switch to peritoneal dialysis or home HD, or
relocate to a non-study center.
We will use a log rank procedure to analyze the effect of
the interventions on the two co-primary composite
outcomes. Subjects who die before 1 year will be ranked
based on survival time (lowest¼ shortest survival). The
remainder will be ranked based on the change in the PHC
score from baseline to the end of follow-up, with the
patient having the largest decline in PHC assigned the next
lowest rank above the patient with the latest death. Follow-
up will be censored at the time of loss to follow-up or
transplantation, or at 12 or 14 months if the subject
survives but no PHC score is available. We will compare
between-group ranks using the log-rank test which allows
the integration of both survival time and a quantitative
measure, (such as the change in PHC score), in the same
outcome. The LVMI composite outcome will be analyzed
similarly. Hochberg’s procedure will be used to maintain a
study-wise type 1 error of two-tailed alphao0.05 for the
co-primary outcomes.34
We will analyze the effects of the interventions on each of
the quantitative main secondary outcomes, by relating the
change from baseline to 12 or 14 months to the randomized
treatment assignment, while controlling for clinical center,
baseline level of the outcome, and five pre-specified baseline
covariates: age, race, years of dialysis, diabetic status, and
serum albumin. For subjects with missing end of study
measurements, a mixed effects model will be used to take into
account the change from baseline to an early assessment (4 or
5 months) to estimate change to 12 or 14 months.
We will analyze the effects of the interventions on the rates
of non-access hospitalizations and death by treating non-
access hospitalizations and death as correlated event-time
outcomes. The joint analysis of both outcomes will be
stratified by type of outcome and clinical center, with
treatment group and the pre-specified covariates included as
independent variables.
Interpreting a trial with multiple intermediate outcomes
We will interpret positive effects on both co-primary
outcomes (adjusted for type 1 error) as providing strong
evidence of overall benefit of the intervention. If there is a
significant effect on only one co-primary outcome, or
significant effects in opposite directions for the co-primary
outcomes, the implications regarding the overall benefit to
patients will be ambiguous.
We will interpret significant treatment effects on main
secondary outcomes as establishing a treatment effect on
the associated outcome domain. Because we regard each of
the outcome domains as conceptually distinct, we will test the
effects of the interventions on each of the main secondary
outcomes at the 0.05 level without adjustment for multiple
comparisons. However, to account for the study-wide risk of
type 1 error, we will evaluate the probabilities of obtaining
one or more positive results for the main secondary
outcomes under the joint null hypothesis of no treatment
effects on any of these outcomes following completion of the
trials. Further, we will not infer a definitive overall clinical
benefit in the absence of significant effects for the two co-
primary end points. Finally, we will consider the effects of
daily and nocturnal HD on patient safety and treatment
burden when interpreting the clinical implications of these
interventions.
Statistical power
We estimated the minimum detectable effect sizes for the two
co-primary composite outcomes by statistical simulation
using a log-rank test with adjustment of the Type 1 error rate
using Hochberg’s procedure, whereby the threshold used to
test the significance of each of the two co-primary composite
end points depends on the observed difference in the other
outcome. Assuming a 20% reduction in mortality, the sample
size of 250 patients has 90% power to detect effects of 4.6–5.0
points in the 1-year change in SF-36 PHC score, and 12.1 to
13.3 g/m2 in the 1-year change in LVMI. Assuming only 85%
of participants successfully complete the home training
program, in the Nocturnal Trial, the minimum detectable
differences range from 5.4 to 5.8 points for the PHC score,
and 14.2 to 15.2 g/m2 for LVMI. A change of 3–5 points in the
SF-36 PHC score has been suggested to be clinically
significant,35 and a 10% change in LVMI has been shown
to predict change in mortality risk.26 The estimated
minimum detectable effect sizes for the co-primary and
main secondary outcomes are summarized in Table 6.
Interim analyses
We did not specify a formal stopping rule for efficacy because
none of the intermediate outcomes were judged to be
sufficiently definitive to warrant early termination of the trial.
SPECIFIC METHODOLOGICAL ISSUES
Vanguard design
Given that experience with frequent HD has been limited to
small observational studies of select patients in a few centers,
we were uncertain whether: 250 patients could be randomi-
zed into each trial; centers could effectively schedule 6
weekly in-center treatments; centers could successfully train
subjects for home nocturnal HD; or if subjects would adhere
to the prescribed treatments. Accordingly, we are assessing
feasibility of each trial during the first 12 months of
enrollment, designated as the Vanguard phase. Throughout
this period, we are carefully monitoring the progress of the
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trials in achieving pre-defined recruitment and adherence
benchmarks, so that we can make protocol changes thereafter
as required. As noted above, owing to low recruitment rates,
we are currently considering changes to the Nocturnal Trial
protocol. At the end of the Vanguard phase, the Data Safety
and Monitoring Board will inform the National Institutes of
Health about the advisability of continuing one or both trials.
Employed successfully in other trials,36,37 this phased
approach combining pilot and efficacy components into a
single study allows subjects enrolled in the feasibility phase to
be included in the final analysis of primary and secondary
outcomes.
Methods to protect against bias
Given that the interventions are by necessity unblinded, we
have implemented several measures aimed to reduce bias.
First, to reduce the chance that study personnel might
influence assessment of outcomes and patient responses,
LVMI will be assessed by a single radiologist blinded to
subjects’ treatment assignments, and the HRQL and other
instruments will be administered centrally by telephone by
blinded interviewers. Instruments and tests that require in-
person interview will be administered by study coordinators
using standard scripts.
Second, enthusiasm for frequent HD may potentially
influence the provision of care in the frequent HD groups. To
attenuate this potential bias, co-interventions will be
standardized between groups wherever possible. Subjects in
both treatment arms at a given center will receive the same
type of dialyzers, reuse policy, and water quality. The Data
Coordinating Center will provide regular feedback to treating
nephrologists of study subjects who persistently fall outside
of hemoglobin, phosphorus, and other laboratory targets
stipulated by National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative guidelines.
Third, subjects on frequent HD may perceive improve-
ments in their HRQL that have more to do with the novelty
of the therapy than to its true benefits. To detect this
phenomenon, we will compare 4-month effects on HRQL to
those at 12 months.
Finally, reductions in extracellular fluid volume that may
occur with frequent HD could potentially influence the
assessment of LVMI, and concentrations of hemoglobin,
albumin, and other biochemical parameters. LVMI will be
assessed by magnetic resonance imaging, as it provides direct
measurements of LVM and thus is less subject to error in the
presence of left ventricular dilatation than echocardiogra-
phy.38,39 For biochemical outcomes, 1-month values will be
used instead of baseline values in sensitivity analyses. In
addition, we will conduct bioelectrical impedance analysis to
explore changes in intra- and extracellular fluids and body
composition.40
Strategies to minimize protocol non-adherence
Protocol non-adherence results in loss of statistical power in
an intention-to-treat analysis. We are employing multiple
Table 6 | Estimated detectable effect sizes for co-primary and main secondary outcomesa,b
Co-Primary Outcomes
Outcome
Change in Other
Primary Outcome SD of 1-yr Changec 80% Power 90% Power
LVMI and mortality 0 24.0 g/m2 11.3 g/m2 13.0 g/m2
2.28 U 10.9 g/m2 12.6 g/m2
4.56 U 10.3 g/m2 12.1 g/m2
SF-36 RAND PHC score and mortality 0 8.28 U 4.3 U 5.0 U
6 g/m2 4.1 U 4.8 U
12 g/m2 3.9 U 4.6 U
Main secondary outcomes
Outcome SD of 1-yr Changec 80% Power 90% Power
SF-36 RAND PHC Score (units) 8.28 3.4 3.9
LVMI (g/m2) 24.0 9.7 11.2
Average serum albumin (g/dl) 0.296 0.12 0.14
Average serum phosphate (mg/dl) 1.66 0.67 0.78
Beck depression inventory score (no. of SD) — 0.40 0.47
Trail making test B score (no. of SD) — 0.40 0.47
Rate of non-access hospitalizations or death (RRR) — Daily Trial: 39%
Nocturnal Trial: 45%
Daily Trial: 45%
Nocturnal Trial: 50%
SD, standard deviation, RRR, relative risk reduction; yr, year.
aEstimates shown for continuous outcomes are for the Daily Trial. The Nocturnal Trial estimates are similar.
bAssumptions: (1) the target sample size of 250 randomized patients is achieved, (2) survival is exponentially distributed, with a rate of 12% per year in the Daily Trial, and 7%
per year in the Nocturnal Trial, (3) transplantation is exponentially distributed, with a rate of 4% per year in the Daily Trial, and 6% per year in the Nocturnal Trial, (4) the rate of
non-access hospitalizations in the control group is 1.19 per patient year, (5) 1-year measurements in the outcomes are obtained in 80% of randomized patients, (6) the
changes in the continuous outcomes are normally distributed, (6) two-tailed alpha=0.05 by Hochberg’s procedure for the primary outcomes, (8) two-tailed alpha=0.05 for
each of the secondary outcomes. The mortality, transplant, and loss to follow-up rates, and the SD of the changes in continuous outcomes are based on estimates obtained
from the HEMO Study database. The SD of the change in the LVMI was obtained from Pitt et al.43
cOne-year change refers to 12-month change in Daily Trial, and 14-month change in Nocturnal Trial.
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strategies to reduce non-adherence, and maintain maximal
separation between the two arms in each trial.
In the Daily Trial, all subjects must successfully complete a
‘pseudo-run-in’ before randomization. Subjects come to the
HD unit for 6 days consecutively to confirm they can tolerate
the demanding schedule and can arrange daily transport-
ation. Subjects considered for the Nocturnal Trial undergo a
multidisciplinary assessment of their capacity for home HD.
The home’s suitability, including space, electricity, plumbing,
and water quality is also evaluated, and subjects agree to any
required home modifications before randomization.
After randomization, if a subject assigned to frequent HD
is unable or unwilling to continue with six times weekly
therapy, we will attempt to approximate the weekly target
dose with a revised prescription of reduced treatment time
and/or reduced frequency in a hierarchy of alternative
options (e.g., five times per week with slightly longer session
length). If the number of sessions per week is reduced, we will
attempt to have the subject return to his or her assigned
regimen as soon as possible.
Characterizing non-dialytic aspects of the interventions
In-center daily HD is a complex intervention, involving not
only the provision of increased HD dose, but also the
potential for significantly increased interaction with the
health-care team. Compared with subjects on conventional
HD, subjects on in-center daily HD may be reminded to take
medications, have blood pressure assessments, and receive
nutritional counseling more often. Thus, any HRQL or
physiological benefits conferred by daily HD may be due, in
part, to increased surveillance and medical care, rather than
increased HD dose. Although home nocturnal HD will
probably reduce day-to-day contact with dialysis providers,
the home environment introduces other confounders. It is
impossible to standardize these aspects of care between
treatment arms; rather they are part of the complex trial
interventions. We are characterizing several non-dialytic
aspects of care in selected centers.
Assessments of generalizability and implementation of
frequent HD
Subjects entered in randomized trials often differ from the
population from which they were drawn.41 Although this is
often owing to select eligibility criteria, the FHN trials have
other barriers. The increased cost and inconvenience of
traveling to the HD unit twice as often may deter patients
from in-center daily HD, and daily transportation may not be
available for all those who are willing. Some potential
subjects may not have suitable home environments or be able
to be trained for nocturnal HD, whereas others may have
fears about performing the procedure themselves, or an
aversion to ‘medicalize’ their homes.42 Differential inclusion
of study subjects by their sociocultural or socioeconomic
characteristics will limit generalizability of the trials’ results.41
We will attempt to limit barriers to recruitment for all
subjects, particularly those of minority and disadvantaged
backgrounds. In addition, the National Institutes of Health
will provide supplemental funding to cover subjects’ travel
and other costs, if needed.
To better understand factors leading to non-participation,
select centers will collect limited demographic data and
reason(s) for non-enrolment for all HD patients in the
participating HD facility. We are collecting the principle
reasons for dropout during baseline among subjects who
enroll but are not randomized. In the Nocturnal Trial, we are
capturing training time, failure rate, and reasons for training
failure. These data will aid recruitment efforts, guide
assessments of generalizability, and provide insight on how
frequent HD might be implemented outside the trials.
CONCLUSION
The FHN clinical trials will test the feasibility, safety and
efficacy of frequent in-center and home nocturnal HD
compared with conventional in-center HD, and provide
information on how frequent HD may be implemented in
multiple centers. Although feasibility concerns and resource
limitations prohibit the conduct of a ‘mega-trial’ adequately
powered to detect clinically and statistically significant
differences in mortality, the FHN trials will help to elucidate
whether more frequent HD might improve outcomes for the
many persons with end-stage renal disease whose health
cannot be adequately restored with conventional dialysis
strategies.
ACKNOWLEDGMENTS
The funds for these trials were received from the National Institutes
of Health NIDDK, Centers for Medicare and Medicaid Services,
Fresenius Medical Care Canada, the Renal Research Institute, and
Satellite Health Care. Dr Suri is supported by a Randomized
Controlled Trials Mentoring Award from the Canadian Institutes of
Health Research. Dr Garg is supported by a Clinician Scientist Award
from the Canadian Institutes of Health Research.
REFERENCES
1. US Renal Data Systems. USRDS 2000 Annual Data Report. National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases. Bethesda MD 2000.
2. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients
with end-stage renal disease in the United States to the year 2010.
J Am Soc Nephrol 2001; 12: 2753–2758.
3. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage
renal disease patients. Am J Kidney Dis 2001; 38: 443–464.
4. Merkus MP, Jager KJ, Dekker FW et al. Quality of life over time in dialysis:
the Netherlands Cooperative Study on the Adequacy of Dialysis.
NECOSAD Study Group. Kidney Int 1999; 56: 720–728.
5. US Renal Data Systems. USRDS 2000 Annual Data Report. National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases.Bethesda MD 2000.
6. Canadian Organ Replacement Registry##2003. http://secure.cihi.ca/
cihiweb/dispPage.jsp?cw_page=statistics_results_topic_dialysis_e&
cw_topic=Health%20Conditions&cw_subtopic=Dialysis (accessed August
2006).
7. Depner TA. Daily hemodialysis efficiency: an analysis of solute kinetics.
Adv Ren Replace Ther 2001; 8: 227–235.
8. Gotch FA, Levin NW. Daily dialysis: the long and the short of it. Blood Purif
2003; 21: 271–281.
9. Suri RS, Nesrallah GE, Mainra R et al. Daily hemodialysis: a systematic
review. Clin J Am Soc Nephrol 2006; 1: 33–42.
10. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect
of nocturnal hemodialysis on blood pressure, left ventricular
Kidney International (2007) 71, 349–359 357
RS Suri et al.: FHN Trials Design t e c h n i c a l n o t e s
hypertrophy, anemia, mineral metabolism, and health-related quality of
life. Kidney Int 2005; 67: 1500–1508.
11. McFarlane PA. Reducing hemodialysis costs: conventional and quotidian
home hemodialysis in Canada. Semin Dial 2004; 17: 118–124.
12. I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy:
update 2000. Am J Kidney Dis 2001; 37: S7–S64.
13. Mowatt G, Vale L, MacLeod A. Systematic review of the effectiveness
of home versus hospital or satellite unit hemodialysis for people with
end-stage renal failure. Int J Technol Assess Health Care 2004; 20:
258–268.
14. Woods JD, Port FK, Stannard D et al. Comparison of mortality with home
hemodialysis and center hemodialysis: a national study. Kidney Int 1996;
49: 1464–1470.
15. Bliwise DL, Kutner NG, Zhang R, Parker KP. Survival by time of day of
hemodialysis in an elderly cohort. JAMA 2001; 286: 2690–2694.
16. Quintaliani G, Buoncristiani U, Fagugli R et al. Survival of vascular access
during daily and three times a week hemodialysis. Clin Nephrol 2000; 53:
372–377.
17. Woods JD, Port FK, Orzol S et al. Clinical and biochemical correlates of
starting ‘daily’ hemodialysis. Kidney Int 1999; 55: 2467–2476.
18. Lindsay RM, Leitch R, Heidenheim AP, Kortas C. The London Daily/
Nocturnal Hemodialysis Study – study design, morbidity, and mortality
results. Am J Kidney Dis 2003; 42: 5–12.
19. Ting GO, Kjellstrand C, Freitas T et al. Long-term study of high-
comorbidity ESRD patients converted from conventional to short daily
hemodialysis. Am J Kidney Dis 2003; 42: 1020–1035.
20. Kooistra MP, Vos PF. Daily home hemodialysis: towards a more
physiological treatment of patients with ESRD. Semin Dial 1999; 12:
424–430.
21. Al Hejaili F, Kortas C, Leitch R et al. Nocturnal but not short hours
quotidian hemodialysis requires an elevated dialysate calcium
concentration. J Am Soc Nephrol 2003; 14: 2322–2328.
22. Hays RD, Morales LS. The RAND-36 measure of health-related quality
of life. Ann Med 2001; 33: 350–357.
23. DeOreo PB. Hemodialysis patient-assessed functional health status
predicts continued survival, hospitalization, and dialysis-attendance
compliance. Am J Kidney Dis 1997; 30: 204–212.
24. Mapes DL, Bragg-Gresham JL, Bommer J et al. Health-related quality
of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Am J Kidney Dis 2004; 44: 54–60.
25. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes study short
form-36: a consistent and powerful predictor of morbidity and mortality
in dialysis patients. Am J Kidney Dis 2004; 44: 54–60.
26. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular
hypertrophy in and survival of patients receiving hemodialysis: follow-up
of an interventional study. J Am Soc Nephrol 2001; 12: 2759–2767.
27. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular
hypertrophy is the strongest predictor of sudden cardiac death in
haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004;
19: 1829–1834.
28. Zoccali C, Benedetto FA, Mallamaci F et al. Left ventricular mass
monitoring in the follow-up of dialysis patients: prognostic value of left
ventricular hypertrophy progression. Kidney Int 2004; 65: 1492–1498.
29. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life
on quotidian hemodialysis. Am J Kidney Dis 2003; 42: 36–41.
30. Traeger J, Galland R, Delawari E et al. Six years’ experience with short daily
hemodialysis: do the early improvements persist in the mid and long
term? Hemodial Int 2004; 8: 151–158.
31. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus
conventional hemodialysis on left ventricular hypertrophy and
inflammatory markers: a prospective, controlled study. J Am Soc Nephrol
2005; 16: 2778–2788.
32. Fagugli RM, Reboldi G, Quintaliani G et al. Short daily hemodialysis: blood
pressure control and left ventricular mass reduction in hypertensive
hemodialysis patients. Am J Kidney Dis 2001; 38: 371–376.
33. Chan CT, Floras JS, Miller JA et al. Regression of left ventricular
hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;
61: 2235–2239.
34. Hochberg YA. A sharper Bonferroni procedure for multiple tests of
significance. Biometrika 1988; 75: 800–803.
35. Samsa G, Edelman D, Rothman ML et al. Determining clinically important
differences in health status measures: a general approach with illustration
to the health utilities index mark II. Pharmacoeconomics 1999; 15:
141–155.
36. Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1
infection. J Clin Virol 2001; 22: 289–295.
37. Cartmel B, Dziura J, Cullen MR et al. Changes in cholesterol and
triglyceride concentrations in the Vanguard population of the Carotene
and Retinol Efficacy Trial (CARET). Eur J Clin Nutr 2005; 59: 1173–1180.
38. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular
mass by cardiovascular magnetic resonance. Hypertension 2002; 39:
750–755.
39. Stewart GA, Foster J, Cowan M et al. Echocardiography overestimates left
ventricular mass in hemodialysis patients relative to magnetic resonance
imaging. Kidney Int 1999; 56: 2248–2253.
40. Fisch BJ, Spiegel DM. Assessment of excess fluid distribution in chronic
hemodialysis patients using bioimpedance spectroscopy. Kidney Int 1996;
49: 1105–1109.
41. Guyatt G, Cook D, Devereaux PJ et al. Therapy. In Guyatt G, Rennie D
(eds). Users’ Guide To The Medical Literature. pp 55–79##Chicago: AMA
Press, 2002.
42. McLaughlin K, Manns B, Mortis G et al. Why patients with ESRD do not
select self-care dialysis as a treatment option. Am J Kidney Dis 2003; 41:
380–385.
43. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and
eplerenone/enalapril in patients with essential hypertension and left
ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Circulation 2003; 108: 1831–1838.
Appendix: FHN Trial Group
Chair, Steering Committee: Kliger A; NIDDK: Eggers P,
Narva A, Star R; Centers for Medicare and Medical Services:
Augustine B, Mohr P; Data Coordinating Center – Cleveland
Clinic: Beck G (PI), Fu Z, Gassman J, Greene T, Daugirdas J,
Hunsicker L, Larive B, MacKrell J, Wiggins K, Sherer S, Weiss
B; Central MRI Core – Ohio State University and Mt. Sinai
Medical Center: Rajagopalan S, Sanz J, Dellagotto S, Kariisa
M; Central Quality of Life Core – University of Pittsburgh:
Unruh M; Central Holter Core– Toronto General Hospital:
Chan C; Biospecimen Repository – Fisher BioServices: Frome
R, Higgins H, Ke S, Snell C; Data Safety and Monitoring
Board: Eknoyan G (Chair), Appel L, Cheung A, Derse A,
Kramer C, Geller N, Grimm R, Henderson L, Prichard S,
Roecker E; Daily Trial Clinical Sites – University of
California San Francisco (UCSF) Consortium: Chertow G
(PI); UCSF and San Francisco Bay Area; Chertow G, Kurella
M, McCulloch C, Painter P, Gorodetskaya I, Tichy M; UC
Davis and Sacramento Area: Depner T, Kaysen G, Suter M; El
Camino Hospital and Satellite Health Care: Ting G, Moran J,
Moran B, Coplon N, Doss S, Rogers J, Dominguez A, Atwal J;
UCLA and Los Angeles Area: Nissenson A, Goodman W,
Salusky I, Schweitzer S, Rivas M, Smith M, Gayda P; UCSD
and San Diego Area: Mehta R, Pepas J, Bharti B; University of
Texas, San Antonio: Ayus J, Achinger S, Gutierrez M, Renal
Research Institute (RRI) New York Consortium: Levin N
(PI); Carter M, Sergeyeva O, Kuhlmann M, Handelmen G,
Gotch F, Finkelstein F, Kimmel P, Lacson E, Ornt D; RRI New
York City: Levin N, Kotanko P, Kaufman A, Winchester J,
Meisels I, Chang J, Fofie Y, Ramos R; University of Western
Ontario: Suri R, Garg A, Lindsay R, Bullas R; Wake Forest
University School of Medicine: Rocco M, Kaufman T;
Vanderbilt University Medical Center: Schulman G, McLeroy
S, Sika M, Leavell E; Barnes Jewish/Washington University:
Miller B, Schussler R, Riley J; Nocturnal Trial Clinical Sites –
Wake Forest University School of Medicine (WFUSM)
Consortium: Rocco M (PI); Barnes-Jewish/Washington Uni-
versity: Miller B, Riley J, Schuessler R; Lynchburg Nephrology
358 Kidney International (2007) 71, 349–359
t e c h n i c a l n o t e s RS Suri et al.: FHN Trials Design
Physicians: Lockridge R, Pipkin M, Peterson C, Rubin
Dialysis: Hoy C, Fensterer A; University of Iowa: Stokes J,
Somers D, Hilkin A, Lilli K, Wallace W; University of Toronto:
Chan C, McGrath-Chong M; University of British Columbia:
Copland M, Levin A, Sioson L, Cabezon E, Kwan S;
University of Western Ontario: Lindsay R, Suri R, Champagne
J, Bullas R, WFUSM: Burkart J, Rocco M, Kaufman T;
Humber River Regional Hospital: Pierratos A, Chan W
Kidney International (2007) 71, 349–359 359
RS Suri et al.: FHN Trials Design t e c h n i c a l n o t e s
